Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parrondo

Showing results (221-230 of 234) with videos related to

Pageof 24
Sort By:
Haematologica|March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasoneRicardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Blood Advances|February 24, 2026
Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World AnalysisCarlyn Rose Tan, Saad Z Usmani, Andriy Derkach, et al.
Circulation|November 10, 2025
High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled AnalysisNiklas Dyrby Johansen, Daniel Modin, Jacobo Pardo-Seco, et al.
Lancet (London, England)|October 20, 2025
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysisNiklas Dyrby Johansen, Daniel Modin, Jacobo Pardo-Seco, et al.
Blood Cancer Journal|April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomesAbiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
Blood|July 26, 2023
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomasUdit Yadav, Shaji K Kumar, Linda B Baughn, et al.
Journal of the American College of Cardiology|February 18, 2026
High-Dose Influenza Vaccination in Atherosclerotic Cardiovascular Disease: A Multinational Pooled Analysis of DANFLU-2 and GALFLU (FLUNITY-HD)Manan Pareek, Niklas Dyrby Johansen, Daniel Modin, et al.
Blood|October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Blood Advances|April 22, 2026
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvementKenneth Jc Lim, Maximilian Johannes Steinhardt, Matthew J Rees, et al.
Pageof 24

Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
Haematologica|March 5, 2026
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasoneRicardo D Parrondo, Ricardo De Menezes, Hanna Sledge, et al.
Blood Advances|February 24, 2026
Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World AnalysisCarlyn Rose Tan, Saad Z Usmani, Andriy Derkach, et al.
Circulation|November 10, 2025
High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled AnalysisNiklas Dyrby Johansen, Daniel Modin, Jacobo Pardo-Seco, et al.
Lancet (London, England)|October 20, 2025
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysisNiklas Dyrby Johansen, Daniel Modin, Jacobo Pardo-Seco, et al.
Blood Cancer Journal|April 4, 2025
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomesAbiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, et al.
Blood|July 26, 2023
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomasUdit Yadav, Shaji K Kumar, Linda B Baughn, et al.
Journal of the American College of Cardiology|February 18, 2026
High-Dose Influenza Vaccination in Atherosclerotic Cardiovascular Disease: A Multinational Pooled Analysis of DANFLU-2 and GALFLU (FLUNITY-HD)Manan Pareek, Niklas Dyrby Johansen, Daniel Modin, et al.
Blood|October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myelomaSurbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Blood Advances|April 22, 2026
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvementKenneth Jc Lim, Maximilian Johannes Steinhardt, Matthew J Rees, et al.
Pageof 24